Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
24.94
-0.72 (-2.81%)
At close: May 1, 2026, 4:00 PM EDT
24.46
-0.48 (-1.92%)
After-hours: May 1, 2026, 7:27 PM EDT
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
68
Market Cap
874.22M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 210.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Theravance Biopharma | 107.46M |
| ARS Pharmaceuticals | 84.28M |
| MeiraGTx Holdings | 81.39M |
| Arbutus Biopharma | 14.08M |
| Evommune | 13.00M |
| Janux Therapeutics | 10.00M |
ANRO News
- 12 days ago - Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression - Business Wire
- 4 weeks ago - Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements - Business Wire
- 6 weeks ago - Alto Neuroscience Transcript: Stifel 2026 Virtual CNS Forum - Transcripts
- 6 weeks ago - Alto Neuroscience Announces $120 Million Private Placement Financing - Business Wire
- 6 weeks ago - Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights - Business Wire
- 7 weeks ago - Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - Business Wire
- 2 months ago - Alto Neuroscience Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Business Wire